, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date , Chairman and CEO of Citius stated, "Our solid execution since the beginning of the year sets us up for potentially transformative catalysts in the coming months. Mino-Lok's strong Phase 3 topline results support its potential to become part of the standard of care for treating catheter-related bloodstream infections.
Mino-Lok would also have a first and only advantage in a market with no approved or investigational products for salvaging infected central venous catheters. For LYMPHIRTM, the FDA is currently reviewing our Biologics License Application, with an expected decision on . We are preparing for near-term commercialization of LYMPHIR if approved.
These near-term catalysts should enable the company to optimize its current cash runway, future cash needs, as well as create potential non-dilutive cash opportunities. "Our primary purpose and mission for these late-stage assets is to provide best-in-class, highly effective treatment options for patients and caregivers," Mazur added. "Ultimately, we believe our achievements and milestones offer powerful levers for value creation.
" Citius significantly advanced its two late-stage product candidate.